# Lung Volume Reduction Surgery > Lung volume reduction surgery for NEET-PG Surgery: NETT selection, upper-lobe heterogeneous emphysema benefit, high-risk exclusion and staple-line air leaks. - Canonical URL: https://prepelephant.com/topics/neet-pg/surgery/lung-volume-reduction-surgery - Exam / course: NEET-PG · Subject: Surgery - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Lung Volume Reduction Surgery", PrepElephant, https://prepelephant.com/topics/neet-pg/surgery/lung-volume-reduction-surgery ## Direct answer Removing a quarter or so of the most destroyed upper-lobe tissue — lung volume reduction surgery — restores the working position of the diaphragm and chest wall in selected patients with severe heterogeneous emphysema, improving mechanics, exercise capacity and quality of life; it is not a cancer operation and does not meaningfully improve survival across the board. The National Emphysema Treatment Trial (NETT) defined who benefits: upper-lobe-predominant disease with low baseline exercise capacity gained the most, while patients with FEV1 at or below 20% predicted plus either a DLCO at or below 20% or a homogeneous pattern had prohibitive 30-day mortality (about 16%) and should not be operated on. ## What you must remember - Physiological logic: hyperinflated emphysematous lungs flatten the diaphragm and splint the chest wall; resecting the most useless 20–30% restores elastic recoil balance and diaphragmatic curvature — the mechanism examiners want articulated. - NETT selection: severe emphysema, FEV1 at or below about 45% predicted, hyperinflation (elevated RV and TLC), abstinence from smoking, and completion of pulmonary rehabilitation before and after surgery. - The NETT high-risk contraindication: FEV1 at or below 20% predicted AND either DLCO at or below 20% or homogeneous emphysema — 16% 30-day mortality in that subgroup, the number to quote. - Best responders: upper-lobe-predominant heterogeneous disease with low exercise capacity; homogeneous disease gains little. - Approach: bilateral VATS or median sternotomy, stapled wedge resection of apical segments, staple lines buttressed with bovine pericardial strips or similar reinforcement to limit air leaks. - The signature complication is prolonged air leak — fragile emphysematous parenchyma does not hold staples well; others include respiratory failure, pneumonia and arrhythmia. - Bronchoscopic alternative: endobronchial valves in selected patients with upper-lobe disease and intact fissures (collateral ventilation assessed before placement). - Mandatory prehabilitation: smoking cessation and a structured pulmonary rehabilitation programme are conditions of surgery, not suggestions — operating on a current smoker or an unrehabilitated patient is a known error. ## Selecting a patient, end to end A 64-year-old ex-smoker with severe COPD is housebound by breathlessness despite maximal inhalers, ambulatory oxygen and six months of rehabilitation. Pulmonary function shows FEV1 28% predicted, residual volume 210% predicted, TLC 128%, DLCO 34%; the perfusion scan and CT show marked upper-lobe-predominant destruction with relatively preserved bases; a 6-minute walk of 110 metres documents low exercise capacity. Her profile maps squarely onto the NETT-favoured subgroup: heterogeneous, upper-lobe-predominant, low exercise capacity — and critically, she is not in the high-risk box (FEV1 and DLCO both above 20%, pattern heterogeneous). The operation is planned as bilateral VATS upper-lobe reduction: buttressed stapled wedges remove the apical third of each upper lobe. On the table the anaesthetist uses lung isolation and permissive hypercapnia; postoperatively the risks she was consented for — prolonged air leak (the commonest), respiratory failure, pneumonia — are managed with early extubation, aggressive physiotherapy and epidural analgesia to keep her coughing. At follow-up her FEV1 and walking distance improve and daytime oxygen is stopped — the outcome the trial predicted for this group. Contrast the man with diffuse homogeneous emphysema, FEV1 18% and DLCO 19%: the NETT's high-risk criteria exclude him — his path is medical management, rehabilitation, and transplant or valve assessment. ## Where students slip The commonest conceptual error is describing LVRS as "removing bad lung so the good lung works better" without the mechanical argument — it is the restoration of diaphragmatic position and chest-wall mechanics, plus improved elastic recoil of the remaining lung, that carries the marks. The second is not knowing the exclusion: candidates offer surgery to the very patients the NETT showed die from it, and the FEV1-plus-DLCO 20% rule is precisely the examinable line. The third is forgetting that rehabilitation is a prerequisite rather than an afterthought; the trial's design made rehabilitation part of the treatment, and answers that omit it read as operative enthusiasm without programme discipline. ## Frequently asked questions ### How much lung is removed in LVRS? Roughly 20–30% of the most emphysematous tissue, usually the apical portions of both upper lobes, taken as buttressed stapled wedge resections. ### Which patients benefit most? Those with upper-lobe-predominant heterogeneous emphysema and low baseline exercise capacity, established by the NETT as the subgroup with the largest gains in function and quality of life. ### Which patients are excluded as high-risk? Those with FEV1 at or below 20% predicted together with either DLCO at or below 20% or a homogeneous pattern — the NETT reported about 16% 30-day mortality in this group. ### What is the commonest operative complication? Prolonged air leak from fragile emphysematous staple lines, mitigated by buttressing material, careful ventilation and patience with chest drains. ### Does LVRS improve survival? Not overall in the trial population; benefits are functional — exercise capacity, quality of life and oxygen independence — with survival advantage confined to selected favourable subgroups. ### What is the bronchoscopic alternative? Endobronchial valve placement to collapse the most destroyed lobe, suitable for selected patients with upper-lobe-predominant disease, intact fissures and no collateral ventilation on physiological testing.